From serendipity to essential protac profiling

The microcosmos of biological processes is complex and full of surprises.

This is also the case for a new preprint from Richert, Nลฏskovรก et al.ย While developing rabeprazole-thalidomide hybrids as targeted protein degraders, the authors observed rapid, reversible ATP depletion in cells. Surprisingly, this effect was attributed to PROTAC molecules with a certain molecular structure.

๐— ๐—ฒ๐—ฐ๐—ต๐—ฎ๐—ป๐—ถ๐˜€๐—บ
Mechanistic studies traced the effect to inhibition of mitochondrial complex I. Oxygen consumption was dose-dependently suppressed and restored by a complex II substrate, pinpointing mitochondrial complex I as the target.

Systematic structural modification of PROTACs revealed that mitochondrial complex I inhibition occurs only in the presence of long, linear molecules that bind in the elongated (~30 ร…) hydrophobic ubiquinone-binding tunnel.

๐—–๐—น๐—ถ๐—ป๐—ถ๐—ฐ๐—ฎ๐—น ๐˜€๐˜๐—ฎ๐—ด๐—ฒ ๐—ฃ๐—ฅ๐—ข๐—ง๐—”๐—–๐˜€ ๐—ฎ๐—น๐˜€๐—ผ ๐—ถ๐—ป๐—ต๐—ถ๐—ฏ๐—ถ๐˜ ๐—บ๐—ถ๐˜๐—ผ๐—ฐ๐—ต๐—ผ๐—ป๐—ฑ๐—ฟ๐—ถ๐—ฎ๐—น ๐—ฐ๐—ผ๐—บ๐—ฝ๐—น๐—ฒ๐˜… ๐—œ
The authors then screened 13 cereblon-recruiting PROTACs and found three clinical stage androgen receptor degraders to be potent inhibitors of mitochondrial complex I:
๐Ÿ”ธ ARV-110: cell-free CI assay pIC50 = 7.66 (22 nM), nearly equipotent with rotenone
๐Ÿ”ธ BMS-986365: CTG/2-DG pEC50 = 6.22 (0.60 ยตM)
๐Ÿ”ธ ARV-766: submicromolar activity with partial inhibition

๐—ฆ๐—ผ๐—น๐˜‚๐˜๐—ถ๐—ผ๐—ป
Structural modification by introducing:
๐Ÿ”ธ “bumps” (e.g., N-acylation of a piperidine linker nitrogen)
๐Ÿ”ธ “kinks” (e.g., using a 1,3-substituted benzimidazolone cereblon recruiter)

A 384-well compatible CTG/2-DG assay was developed to enable routine CI liability screening.

This allowed the authors to abolish mitochondrial complex I inhibition while preserving AR degradation potency in cell-based assays.

๐—ง๐—ต๐—ฒ ๐—ธ๐—ฒ๐˜† ๐˜๐—ฎ๐—ธ๐—ฒ๐—ฎ๐˜„๐—ฎ๐˜†
Mitochondrial complex I inhibition by PROTACs is not target- or recruiter-specific. It appears to be a general feature of long, linear, hydrophobic molecules, a common molecular architecture across bifunctional modalities. The authors propose rational geometric redesign as a generalizable mitigation strategy.

Are you going to implement this assay to your PROTAC development workflows? Let me know your thoughts!

Full preprint: https://lnkd.in/gWC2_jmk

Share your thoughts and leave your comment under my LinkedIn post here.

#DrugDiscovery #PROTACs